Haseeb joined the HDR UK Board of Trustees in January 2025. He is currently Chief Executive Officer (CEO) of Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases. He is an experienced senior leader in the life sciences industry with over 25 years of global leadership experience across pharmaceuticals and biotech.
Prior to joining Purespring, Haseeb was President of Novartis Europe, where he oversaw $15 billion in revenue across 53 markets. He also served as President of Novartis Gene Therapies, leading the launch of Zolgensma, the world’s first blockbuster gene therapy. During his tenure at Novartis, he held multiple global and in-country leadership roles, including Global Head of Value & Access and Managing Director for the UK, Ireland, and Nordics. Before Novartis, he held senior leadership roles at MSD, including Managing Director of MSD Ireland and Greece.
Haseeb has been a strong advocate for innovation in healthcare and expanding patient access to novel treatments. He previously served as President and Chairman of the Board for the Association of the British Pharmaceutical Industry (ABPI) and as a Government Advisor for the UK’s Innovation Expert Group.
